中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

111 records (took 0.038 seconds)

    Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
    44.
    发明授权
    Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith 有权

    公开(公告)号：US09377463B2

    公开(公告)日：2016-06-28

    申请号：US14311412

    申请日：2014-06-23

    Applicant: ETH ZURICH ,  Kantonsspital St. Gallen

    Inventor： Wilhelm Krek ,  Igor Cima ,  Rudolf Aebersold ,  Ralph Schiess ,  Thomas Cerny ,  Silke Gillessen

    IPC: G01N33/53 ,  G01N33/574 ,  G01N33/68

    CPC classification number: G01N33/57434 ,  G01N33/57407 ,  G01N33/6848 ,  G01N2333/47 ,  G01N2333/70525 ,  G01N2333/8146

    Abstract: The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behavior between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behavior between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an Enzyme-Linked Immunosorbent Assay (ELISA) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behavior between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself.

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF TISSUE FIBROSIS
    47.
    发明申请
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF TISSUE FIBROSIS 审中-公开
    用于治疗组织纤维化的组合物和方法

    公开(公告)号：US20140050740A1

    公开(公告)日：2014-02-20

    申请号：US14111338

    申请日：2012-04-12

    Applicant: Paul W. Noble ,  Dianhua Jiang

    Inventor： Paul W. Noble ,  Dianhua Jiang

    IPC: A61K39/395 ,  A61K31/7088

    CPC classification number: A61K39/3955 ,  A61K31/7088 ,  C12Q1/37 ,  G01N2333/8146

    Abstract: Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease.

    Abstract translation: 提供治疗组织纤维化的方法，包括向需要治疗的受试者施用有效量的抑制透明质酸合酶（HAS）或CD44的药剂。 还提供了抑制肌成纤维细胞侵袭或减少肺中基质沉积的方法，所述方法包括向需要治疗的受试者施用有效量的抑制HAS或CD44的药剂。 还提供了确定肺纤维化进展的方法，所述方法包括确定细胞中基质金属蛋白酶表达的水平，以及比较对照细胞的表达水平，其中相对于对照细胞增加的表达水平 表示疾病进展。

Patent Agency Ranking